GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tci Gene Inc (ROCO:6879) » Definitions » EBITDA Margin %

Tci Gene (ROCO:6879) EBITDA Margin % : 7.33% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Tci Gene EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tci Gene's EBITDA for the six months ended in Dec. 2023 was NT$13.5 Mil. Tci Gene's Revenue for the six months ended in Dec. 2023 was NT$184.0 Mil. Therefore, Tci Gene's EBITDA margin for the quarter that ended in Dec. 2023 was 7.33%.


Tci Gene EBITDA Margin % Historical Data

The historical data trend for Tci Gene's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tci Gene EBITDA Margin % Chart

Tci Gene Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
33.37 28.72 35.89 28.45 7.76

Tci Gene Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only 37.72 40.74 11.01 8.28 7.33

Competitive Comparison of Tci Gene's EBITDA Margin %

For the Biotechnology subindustry, Tci Gene's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tci Gene's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tci Gene's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Tci Gene's EBITDA Margin % falls into.



Tci Gene EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Tci Gene's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=25.891/333.855
=7.76 %

Tci Gene's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=13.484/183.992
=7.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tci Gene  (ROCO:6879) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Tci Gene EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Tci Gene's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tci Gene (ROCO:6879) Business Description

Traded in Other Exchanges
N/A
Address
No. 185-1, Gangqian Rd, 10th FLoor, Neihu District, Taipei, TWN
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.

Tci Gene (ROCO:6879) Headlines

No Headlines